AIM ImmunoTech (AIM) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
19 Dec, 2025Opening remarks and agenda
Meeting called to order at 11:00 A.M. Eastern Time on December 16, 2025, with introductions of board members and senior management.
Agenda and rules of conduct were made available to participants via the web portal.
Only stockholders of record as of October 24, 2025, or their proxies, were permitted to participate and vote.
Board and executive committee updates
Directors present included Nancy Bryan, David Chemerow, Ted Kellner, and senior management members.
Peter Rodino acted as Secretary, and Mike Barbera served as Independent Inspector of Elections.
Shareholder proposals
Four proposals were presented: election of five directors, ratification of BDO USA, P.C. as auditor, advisory vote on executive compensation, and advisory vote on frequency of executive compensation votes.
Board recommended voting for all nominees, for ratification of the auditor, for executive compensation, and for annual advisory votes.
Latest events from AIM ImmunoTech
- Ampligen extends survival in pancreatic cancer and is advancing toward a pivotal Phase 3 trial.AIM
Virtual Investor Closing Bell19 Feb 2026 - Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer.AIM
Corporate Connect Webinar Series11 Feb 2026 - Rights offering of up to 12,000 units at $1,000 each, with preferred stock and warrants, managed by Maxim Group LLC.AIM
Registration Filing10 Feb 2026 - Rights offering seeks up to $12M for clinical trials, with significant dilution and compliance risks.AIM
Registration Filing29 Jan 2026 - Rights offering targets $12M for clinical trials and debt, with significant dilution and listing risks.AIM
Registration filing25 Jan 2026 - Q2 net loss narrowed 63% as clinical programs advanced and $10.1M cash supports milestones.AIM
Q2 202423 Jan 2026 - Ampligen plus durvalumab achieves over 60% six-month disease stabilization in metastatic pancreatic cancer.AIM
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Net loss narrowed 53% in Q3 2024; clinical progress and cost cuts offset liquidity risks.AIM
Q3 202413 Jan 2026 - Clinical pipeline advances, expenses down, and NYSE listing prioritized amid ongoing trials.AIM
Q4 202425 Dec 2025